Investigation on the Efficiency of Tonic Chinese Herbal Injections for Treating Dilated Cardiomyopathy Based on Bayesian Network Meta-Analysis

Table 1

Characteristics of the included randomized controlled trials.

Study ID

Sample size (T/C)

Sex (M/F)

Average age (year)

Disease duration (year)

NYHA(T/C)

Treatment group

Solution of Chis

Control group

Course of treatment (day)

Outcomes

II

III

IV

Yang XL 2009

30/30

NR

NR

NR

NR

HQI20 ml + WM

5%GS250 ml

WM

14 d

①

Wu XH 2005

26/26

28/24

E:39.10 ± 17.92; C:41.20 ± 16.81

NR

—

14/15

12/11

HQI30 ml + WM

5%GS250 ml

WM

15 d

①②⑤

Chen DM 2005

60/60

84/36

E:42.5; C:41.7

NR

NR

HQI40 ml + WM

5%GS250 ml

WM

14 d

①

Shang WM 2007

36/36

43/29

59 ± 12

NR

HQI40 ml + WM

5%GS250 ml

WM

14 d

①②

Luo HM 2007

36/32

36/32

E:46 ± 3; C:48 ± 4

E:8.4 ± 0.3; C:8.5 ± 0.2

12/14

14/10

10/8

HQI40 ml + WM

5%GS250 ml

WM

15 d

①⑦

Gao XJ 2010

18/15

24/9

E:42; C:40

E:3–15; C:0.4–15

5/4

7/6

6/5

HQI20 ml + WM

5%GS250 ml/0.9%NS250 ml for diabetic

WM

14 d/course, 2 courses

①②

Lei HF 2011

30/30

60/0

41.5 ± 7.2

NR

NR

HQI20 ml + WM

0.9%NS250 ml

WM

15 d, some patients may be extended to 20∼30 d

①⑦

Liang CC 2001

37/37

42/32

E:56; C55

NR

—

23/14

23/14

SFI20 ml + WM

5%GS100 ml

WM

—

①②④⑥

Que HX 2003

32/28

37/23

E:35–76; C:33–75

E:0.8–15; C:0.8–15

8/7

21/19

3/2

SFI60 ml + WM

5%GS250 ml or 0.9%NS250 ml

WM

14 d

①②⑥

Tang BN 2005

29/29

40/18

E:48.8; C:49.8

NR

1/2

15/17

13/10

SFI60 ml + WM

5%GS250 ml

WM

14 d/course, 2 courses

①②

Yang Y 2009

30/30

42/18

E:42.50 ± 16.81; C:40.52 ± 15.98

NR

—

8/12

22/18

SFI60 ml + WM

5%GS250 ml

WM

14 d

①②⑤⑦

Chen ZG 2009

30/27

42/15

E:21–75; C:20–76

NR

—

20/18

10/9

SFI50 ml + WM

5%GS250 ml/plus insulin for diabetic

WM

14 d

①②④⑤

Lv G 2010

31/30

44/17

E:41.5 ± 10.2; C:40.3 ± 12.5

NR

—

10/11

21/19

SFI50 ml + WM

5%GS250 ml/plus insulin for diabetic

WM

14 d

①②④⑤

Wang CK 2011

50/50

66/34

E:31 ± 9; C:32 ± 9

E:6.1 ± 1.8; C:6.5 ± 1.5

23/21

19/23

8/6

SFI1 ml/(kg·d) + WM

NR

WM

14 d

②③

Nie YJ 2012

38/40

52/26

58.5 ± 10.5

NR

13

45

20

SFI2 ml/(kg·d) + WM

5%GS250 ml

WM

10 d

①②⑤

Yu M 2013

39/40

40/39

40 ± 13

0. 5–12

NR

SFI50 ml + WM

NR

WM

14 d

②③④⑤

Zhang F 2014

40/40

44/36

E:52.1 ± 12.6; C:49.9 ± 13.8

E:6.5 ± 4.6; C:6.2 ± 5.1

NR

SFI50 ml + WM

5%GS250 ml/0.9%NS250 ml

WM

14 d

①

Wang L 2014

42/38

49/31

E:61.8 ± 10.3; C:60.8 ± 9.9

NR

—

12/30

21/17

SFI50 ml + WM

5%GS250 ml

WM

10 d

①②

Qi CH2015

60/60

82/38

E:63.00; C:62.70

NR

—

31/28

29/32

SFI60 ml + WM

5%GS250 ml

WM

14 d

①②⑥

Wu XH 2001

28/28

33/23

E:40.3 ± 15.0; C:41.5 ± 16.8

E:0.1–4.0; C:0.1–4.2

—

16/15

12/13

SI40-60 ml + WM

5%GS250 ml

WM

15 d/course, 2 courses

①②⑤⑦

Zhang YC 2002

50/50

59/41

E:58 ± 15; C:60 ± 16

E:0.5–8.0; C:0.6–8.0

10/10

35/36

5/4

SI60 ml + WM

5%GS250 ml/0.9%NS250 ml

WM

14d

①②⑥

Wang H 2006

30/20

30/20

E:41.0 ± 15.0; C:39.5 ± 13.5

E:0.5–6.0; C:0.4–5.5

11/9

14/9

5/2

SI40-60 ml + WM

5%GS250 ml

WM

14 d/course, 2 courses

①④

Li W 2006

30/22

35/17

E:39.5; C:37.6

E:4.8; C:4.2

13/10

11/8

6/4

SI60 ml + WM

5%GS250 ml/0.9%NS250 ml

WM

14 d

①②④⑥

Wu XL 2009

30/30

42/18

E:45–81; C:41–79

E:0.7–7; C:0.6–8

8/8

16/18

6/4

SI60 ml + WM

5%GS250 ml

WM

14 d

①

Li BH2015

30/30

40/20

53 ± 6

NR

NR

SI50 ml + WM

5%GS500 ml

WM

10 d

①②③④⑦

Shi L 2017

38/38

43/33

E:45.05 ± 7.15; C:46.08 ± 7.12

E: 9.31 ± 3.51; C:9.16 ± 3.37

14/12

15/16

9/10

SI40 ml + WM

5%GS250 ml

WM

14 d/course, 2 courses

①②⑤⑥⑦

Wang NX 2006

15/15

25/5

E:36–59; C:39–58

NR

NR

SMI60 ml + WM

5%GS250 ml/0.9%NS250 ml

WM

15 d

①②

Wang X 2008

30/30

34/26

E:39.6; C:41.2

NR

9/8

15/16

6/6

SMI50 ml + WM

5%GS250 ml

WM

7 d/course, 4 courses

①

Cao Y 2011

111/111

140/82

E:36–59; C:39–58

NR

NR

SMI60 ml + WM

5%GS250 ml

WM

15 d

①

Wang AC 2011

30/30

—

—

NR

NR

SMI100 ml + WM

NR

WM

28 d

①②③⑦

Chen XY 2012

34/34

38/30

42.2

NR

18/19

14/11

2/4

SMI60 ml + WM

5%GS250 ml

WM

14 d

①⑦

Cao L 2012

24/22

31/15

E:42.6 ± 9.8; C:40.1 ± 15.2

NR

—

18/16

6/6

SMI60 ml + WM

5%GS150 ml

WM

14 d

①②⑦

Tian HM 2012

30/30

34/26

E:48.6 ± 5.8; C:49.8 ± 2.5

NR

8/12

14/12

8/6

SMI50 ml + WM

5%GS250 ml

WM

7 d/course, 3 courses

①

Wu JJ 2013

30/30

41/19

—

E:0.3–10; C:0.3–11

NR

SMI60 ml + WM

5%GS250 ml/0.9%NS250 ml for diabetic

WM

14 d

①②⑦

Yan GQ 2014

58/58

62/54

40.6

NR

22/16

28/33

8/9

SMI60 ml + WM

5%GS250 ml

HQI40 ml + WM

15 d

①

Zhao XR 2015

50/50

57/43

E:54.2 ± 4.5; C:54.7 ± 4.2

E: 5.2 ± 1.9; C:5.1 ± 1.5

6/5

25/26

19/19

SMI60 ml + WM

5%GS150 ml

WM

14 d

①②③④⑦

Wang JY 2016

30/30

34/26

E:59.3 ± 8.6; C:60.7 ± 10.2

NR

6/24

10/20

—

SMI100 ml + WM

NR

WM

14 d

①②③⑥

Song CH 2017

50/50

52/48

E:35.25 ± 4.61; C:36.06 ± 4.05

NR

12/10

29/26

9/14

SMI40 ml + WM

5%GS250 ml

WM

14d

①②④⑥⑦

Duan Y 2006

40/42

39/43

E:63.8 ± 4.5; C:59.9 ± 5.2

E:12.6 ± 6.9; C:13.4 ± 7.2

3/4

18/20

19/18

SQFZI250 ml + WM

—

WM

14d

②

Li GK 2014

41/39

44/36

E:67 ± 8; C:66 ± 7

NR

28/25

13/14

—

YQFMI2.6 g + WM

5%GS250 ml

WM

14d

②③④

C, control group; F, female; GS, dextrose solution; HQI, Huangqi injection; M, male; NR, not related; NS, normal saline; SFI, Shenfu injection; SI, Shengmai injection; SMI, Shenmai injection; SQFZI, Shenqi Fuzheng injection; T, treatment group; YQFMI, Yiqifumai injection. Outcomes: ① the clinical effective rate, ② left ventricular ejection fraction, ③ 6-minute walk test, ④ left ventricular end-diastolic dimension, ⑤ heart rate, ⑥ cardiac output, ⑦ ADRs/ADEs.